← Back to All US Stocks

CERS Stock Analysis - CERUS CORP AI Rating

CERS Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001020214
Recently Updated • Analysis: Mar 22, 2026 • SEC Data: 2025-12-31
AI Rating
SELL
78% Confidence

📊 CERS Key Takeaways

Revenue: $233.8M
Net Margin: -6.7%
Free Cash Flow: $1.1M
Current Ratio: 1.73x
Debt/Equity: 1.31x
EPS: $-0.08
AI Rating: SELL with 78% confidence

Investment Thesis

Cerus demonstrates strong top-line growth (+16.1% YoY) and positive free cash flow generation, but fundamental profitability metrics are deeply concerning with negative net margins (-6.7%), operating margins (-3.7%), and poor returns on equity (-24.3%), indicating the company's revenue growth is not translating to sustainable profitability. The high debt-to-equity ratio (1.31x) combined with negative interest coverage (-1.9x) and significant operating losses raises questions about long-term financial viability despite adequate near-term liquidity.

CERS Strengths

  • + Revenue growth of 16.1% YoY demonstrates market demand for products
  • + Positive free cash flow of $1.1M and operating cash flow of $4.8M shows cash generation capability
  • + Adequate short-term liquidity with current ratio of 1.73x and $20.0M cash position

CERS Risks

  • ! Persistently unprofitable with -6.7% net margin and -3.7% operating margin indicating structural profitability challenges
  • ! High leverage with $84.0M long-term debt and 1.31x debt-to-equity ratio combined with negative interest coverage ratio of -1.9x creates financial distress risk
  • ! Deteriorating returns metrics (ROE -24.3%, ROA -7.0%) show the business is not efficiently deploying capital despite revenue growth

Key Metrics to Watch

CERS Financial Metrics

Revenue
$233.8M
Net Income
$-15.6M
EPS (Diluted)
$-0.08
Free Cash Flow
$1.1M
Total Assets
$221.9M
Cash Position
$20.0M

💡 AI Analyst Insight

The relatively thin 0.5% FCF margin may limit capital allocation flexibility.

CERS Profitability Ratios

Gross Margin 6.0%
Operating Margin -3.7%
Net Margin -6.7%
ROE -24.3%
ROA -7.0%
FCF Margin 0.5%

CERS vs Healthcare Sector

How CERUS CORP compares to Healthcare sector averages

Net Margin
CERS -6.7%
vs
Sector Avg 12.0%
CERS Sector
ROE
CERS -24.3%
vs
Sector Avg 15.0%
CERS Sector
Current Ratio
CERS 1.7x
vs
Sector Avg 2.0x
CERS Sector
Debt/Equity
CERS 1.3x
vs
Sector Avg 0.6x
CERS Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CERS Balance Sheet & Liquidity

Current Ratio
1.73x
Quick Ratio
1.17x
Debt/Equity
1.31x
Debt/Assets
70.7%
Interest Coverage
-1.90x
Long-term Debt
$84.0M

CERS 5-Year Financial Trend

CERS 5-year financial data: Year 2021: Revenue $159.5M, Net Income -$71.2M, EPS N/A. Year 2022: Revenue $188.3M, Net Income -$59.9M, EPS $-0.37. Year 2023: Revenue $188.3M, Net Income -$54.4M, EPS $-0.32. Year 2024: Revenue $201.3M, Net Income -$42.8M, EPS $-0.24. Year 2025: Revenue $233.8M, Net Income -$37.5M, EPS $-0.21.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CERUS CORP's revenue has grown significantly by 47% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.21 indicates the company is currently unprofitable.

CERS Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
0.5%
Free cash flow / Revenue

CERS Quarterly Performance

Quarterly financial performance data for CERUS CORP including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2018 $10.8M -$13.4M $-0.11
Q2 2018 $9.5M -$13.3M $-0.10
Q1 2018 $7.0M -$13.9M $-0.11
Q3 2017 $10.2M -$13.4M $-0.12
Q2 2017 $9.3M -$17.0M $-0.16
Q1 2017 $7.0M -$16.9M $-0.17
Q3 2016 $8.0M -$14.1M $-0.14
Q2 2016 $8.8M -$8.5M $-0.17

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CERS Capital Allocation

Operating Cash Flow
$4.8M
Cash generated from operations
Capital Expenditures
$3.7M
Investment in assets
Dividends
None
No dividend program

CERS SEC Filings

Access official SEC EDGAR filings for CERUS CORP (CIK: 0001020214)

📋 Recent SEC Filings

Date Form Document Action
Mar 16, 2026 4 xslF345X05/ownership.xml View →
Mar 16, 2026 4 xslF345X05/ownership.xml View →
Mar 16, 2026 4 xslF345X05/ownership.xml View →
Mar 16, 2026 4 xslF345X05/ownership.xml View →
Mar 16, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about CERS

What is the AI rating for CERS?

CERUS CORP (CERS) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CERS's key strengths?

Revenue growth of 16.1% YoY demonstrates market demand for products. Positive free cash flow of $1.1M and operating cash flow of $4.8M shows cash generation capability.

What are the risks of investing in CERS?

Persistently unprofitable with -6.7% net margin and -3.7% operating margin indicating structural profitability challenges. High leverage with $84.0M long-term debt and 1.31x debt-to-equity ratio combined with negative interest coverage ratio of -1.9x creates financial distress risk.

What is CERS's revenue and growth?

CERUS CORP reported revenue of $233.8M.

Does CERS pay dividends?

CERUS CORP does not currently pay dividends.

Where can I find CERS SEC filings?

Official SEC filings for CERUS CORP (CIK: 0001020214) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CERS's EPS?

CERUS CORP has a diluted EPS of $-0.08.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-12-31 | Powered by Claude AI